Cargando…

Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study

BACKGROUND: Recurrence is the main cause of death in perihilar cholangiocarcinoma (pCCA) patients after surgery. Identifying patients with a high risk of recurrence is important for decision-making regarding neoadjuvant therapy to improve long-term outcomes. AIM: The objective of this study was to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhi-Peng, Chen, Wei-Yue, Wang, Zi-Ran, Liu, Xing-Chao, Fan, Hai-Ning, Xu, Lei, Pan, Yu, Zhong, Shi-Yun, Xie, Dan, Bai, Jie, Jiang, Yan, Zhang, Yan-Qi, Dai, Hai-Su, Chen, Zhi-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071302/
https://www.ncbi.nlm.nih.gov/pubmed/35530316
http://dx.doi.org/10.3389/fonc.2022.849053
_version_ 1784700821902983168
author Liu, Zhi-Peng
Chen, Wei-Yue
Wang, Zi-Ran
Liu, Xing-Chao
Fan, Hai-Ning
Xu, Lei
Pan, Yu
Zhong, Shi-Yun
Xie, Dan
Bai, Jie
Jiang, Yan
Zhang, Yan-Qi
Dai, Hai-Su
Chen, Zhi-Yu
author_facet Liu, Zhi-Peng
Chen, Wei-Yue
Wang, Zi-Ran
Liu, Xing-Chao
Fan, Hai-Ning
Xu, Lei
Pan, Yu
Zhong, Shi-Yun
Xie, Dan
Bai, Jie
Jiang, Yan
Zhang, Yan-Qi
Dai, Hai-Su
Chen, Zhi-Yu
author_sort Liu, Zhi-Peng
collection PubMed
description BACKGROUND: Recurrence is the main cause of death in perihilar cholangiocarcinoma (pCCA) patients after surgery. Identifying patients with a high risk of recurrence is important for decision-making regarding neoadjuvant therapy to improve long-term outcomes. AIM: The objective of this study was to develop and validate a prognostic model to predict recurrence-free survival (RFS) after curative resection of pCCA. METHODS: Patients following curative resection for pCCA from January 2008 to January 2016 were identified from a multicenter database. Using random assignment, 70% of patients were assigned to the training cohort, and the remaining 30% were assigned to the validation cohort. Independent predictors of RFS after curative resection for pCCA were identified and used to construct a prognostic model. The predictive performance of the model was assessed using calibration curves and the C-index. RESULTS: A total of 341 patients were included. The median overall survival (OS) was 22 months, and the median RFS was 14 months. Independent predictors associated with RFS included lymph node involvement, macrovascular invasion, microvascular invasion, maximum tumor size, tumor differentiation, and carbohydrate antigen 19-9. The model incorporating these factors to predict 1-year RFS demonstrated better calibration and better performance than the 8th American Joint Committee on Cancer (AJCC) staging system in both the training and validation cohorts (C-indexes: 0.723 vs. 0.641; 0.743 vs. 0.607). CONCLUSIONS: The prognostic model could identify patients at high risk of recurrence for pCCA to inform patients and surgeons, help guide decision-making for postoperative adjuvant therapy, and improve survival.
format Online
Article
Text
id pubmed-9071302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90713022022-05-06 Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study Liu, Zhi-Peng Chen, Wei-Yue Wang, Zi-Ran Liu, Xing-Chao Fan, Hai-Ning Xu, Lei Pan, Yu Zhong, Shi-Yun Xie, Dan Bai, Jie Jiang, Yan Zhang, Yan-Qi Dai, Hai-Su Chen, Zhi-Yu Front Oncol Oncology BACKGROUND: Recurrence is the main cause of death in perihilar cholangiocarcinoma (pCCA) patients after surgery. Identifying patients with a high risk of recurrence is important for decision-making regarding neoadjuvant therapy to improve long-term outcomes. AIM: The objective of this study was to develop and validate a prognostic model to predict recurrence-free survival (RFS) after curative resection of pCCA. METHODS: Patients following curative resection for pCCA from January 2008 to January 2016 were identified from a multicenter database. Using random assignment, 70% of patients were assigned to the training cohort, and the remaining 30% were assigned to the validation cohort. Independent predictors of RFS after curative resection for pCCA were identified and used to construct a prognostic model. The predictive performance of the model was assessed using calibration curves and the C-index. RESULTS: A total of 341 patients were included. The median overall survival (OS) was 22 months, and the median RFS was 14 months. Independent predictors associated with RFS included lymph node involvement, macrovascular invasion, microvascular invasion, maximum tumor size, tumor differentiation, and carbohydrate antigen 19-9. The model incorporating these factors to predict 1-year RFS demonstrated better calibration and better performance than the 8th American Joint Committee on Cancer (AJCC) staging system in both the training and validation cohorts (C-indexes: 0.723 vs. 0.641; 0.743 vs. 0.607). CONCLUSIONS: The prognostic model could identify patients at high risk of recurrence for pCCA to inform patients and surgeons, help guide decision-making for postoperative adjuvant therapy, and improve survival. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9071302/ /pubmed/35530316 http://dx.doi.org/10.3389/fonc.2022.849053 Text en Copyright © 2022 Liu, Chen, Wang, Liu, Fan, Xu, Pan, Zhong, Xie, Bai, Jiang, Zhang, Dai and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Zhi-Peng
Chen, Wei-Yue
Wang, Zi-Ran
Liu, Xing-Chao
Fan, Hai-Ning
Xu, Lei
Pan, Yu
Zhong, Shi-Yun
Xie, Dan
Bai, Jie
Jiang, Yan
Zhang, Yan-Qi
Dai, Hai-Su
Chen, Zhi-Yu
Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title_full Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title_fullStr Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title_full_unstemmed Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title_short Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
title_sort development and validation of a prognostic model to predict recurrence-free survival after curative resection for perihilar cholangiocarcinoma: a multicenter study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071302/
https://www.ncbi.nlm.nih.gov/pubmed/35530316
http://dx.doi.org/10.3389/fonc.2022.849053
work_keys_str_mv AT liuzhipeng developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT chenweiyue developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT wangziran developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT liuxingchao developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT fanhaining developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT xulei developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT panyu developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT zhongshiyun developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT xiedan developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT baijie developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT jiangyan developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT zhangyanqi developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT daihaisu developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy
AT chenzhiyu developmentandvalidationofaprognosticmodeltopredictrecurrencefreesurvivalaftercurativeresectionforperihilarcholangiocarcinomaamulticenterstudy